Table 1.
Baseline characteristics and COVID-19 management
| Early cohort (n = 254) | Later cohort (n = 120) | Entire cohort (N = 374) | ||||
|---|---|---|---|---|---|---|
| Proportion, unless otherwise specified, % | Patients with available data, n | Proportion, unless otherwise specified, % | Patients with available data, n | Proportion, unless otherwise specified, % | Patients with available data, n | |
| Baseline characteristics | ||||||
| Age at CLL diagnosis, median in years (range) | 62.5 (31 - 92) | 248 | 59 (29-86) | 119 | 61 (29-92) | 367 |
| Age at COVID-19 diagnosis, median in years (range) | 70 (36 - 98) | 254 | 65.5 (29-93) | 120 | 68 (29-98) | 374 |
| Male | 64 | 254 | 65 | 120 | 64 | 374 |
| White | 86 | 249 | 85 | 116 | 85 | 365 |
| CIRS,22 median (range) | 8 (4-32) | 229 | 8 (4-21) | 117 | 8 (4-32) | 346 |
| CLL treatment history | 253 | 119 | 372 | |||
| Never treated | 44 | — | 47 | — | 45 | — |
| Prior therapy | 56 | — | 53 | — | 55 | — |
| Lines of therapy for previously treated patients, median (range) | 1.5 (1-8) | 136 | 1 (1-7) | 61 | 1 (1-8) | 197 |
| Receiving therapy at time of COVID-19 diagnosis | 39 | 254 | 34 | 119 | 38 | 373 |
| Receiving BTK inhibitor at time of COVID-19 diagnosis | 29 | 253 | 21 | 119 | 26 | 372 |
| Receiving venetoclax at time of COVID-19 diagnosis | 8 | 253 | 9 | 119 | 8 | 372 |
| COVID-19 management | ||||||
| Admitted | 85 | 252 | 55 | 119 | 75 | 371 |
| ICU admission | 32 | 250 | 15 | 107 | 27 | 357 |
| Imaging performed | 89 | 245 | 60 | 108 | 80 | 353 |
| Pneumonia on imaging | 88 | 224 | 62 | 82 | 81 | 306 |
| Supplemental oxygen | 78 | 250 | 45 | 112 | 68 | 362 |
| Mechanical ventilation | 25 | 246 | 9 | 111 | 20 | 357 |
| Steroids administered | 42 | 244 | 39 | 112 | 41 | 356 |
CIRS, cumulative illness rating scale.